SHIFT Newsroom

SHIFT Newsroom · GLOBAL

GLP-1 Receptor Agonists Post-Bariatric Surgery Trial Underway

Researchers are investigating the use of GLP-1 receptor agonists after bariatric surgery, with a new trial publishing its rationale, design, and baseline characteristics.

By SHIFT AI Newsroom · Published 10 September 2026

How we prepare and check newsroom articles · Report a correction

The GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial has published its rationale, design, and baseline characteristics. The trial aims to investigate the effects of GLP-1 receptor agonists in patients who have undergone bariatric surgery.

SHIFT’s take

What we think this could mean for you, and what remains uncertain.

The trial's findings could have implications for the management of patients in the UK who have undergone bariatric surgery, potentially informing future treatment guidelines and improving patient outcomes.

Known facts

  • The GRABS trial aims to investigate the use of GLP-1 receptor agonists post-bariatric surgery.

Sources and evidence

← Back to SHIFT Newsroom

Last updated .